Sotatercept-csrk is approved for improving exercise capacity and reducing clinical worsening in PAH patients, following FDA label expansion. The ZENITH trial showed a 76% reduction in major morbidity ...
Adding WINREVAIR to background PAH therapy improved exercise capacity and WHO functional class (FC), and reduced the risk of clinical worsening events, including hospitalization for PAH, lung ...
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Merck (NYSE: MRK), known ...
PAH patients exhibit low physical activity and poor sleep quality, with wearable technology offering objective insights beyond the 6MWD test. Positive correlations exist between deep/REM sleep and ...
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study Adding ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback